TB006 is an investigational drug developed by TrueBinding that has shown promise in reversing dementia-related symptoms in clinical trials. Patients demonstrated cognitive improvements, as indicated by standardized mental assessments. TB006 is currently accessible through the FDA’s Expanded Access Program (EAP), also known as Compassionate Use. While individual outcomes vary and results aren’t guaranteed, TB006 may offer new hope for those suffering from any form of dementia. To learn more, schedule a consultation with an Authorized TB006 Provider.
TB006 targets the root cause of inflammation in the brain. It neutralizes Galectin-3 (Gal-3), a proinflammatory protein linked to immune dysfunction, brain injury, and neuroinflammation. By deactivating Gal-3, TB006 helps restore immune system function and supports the brain’s natural healing process.
No. TB006 is not a cure. It is an investigational therapy still undergoing clinical evaluation. There is currently no known cure for dementia or Alzheimer’s disease.
Traditional Alzheimer’s drugs focus on stimulating brain activity or removing beta-amyloid plaques, offering limited symptom relief without halting disease progression. Many also carry significant side effects like brain swelling or microhemorrhages.
TB006 offers a novel approach: instead of targeting plaques or tangles, it addresses the immune system dysfunction that drives chronic brain inflammation. By neutralizing Galectin-3, TB006 allows the immune system to recover and promotes brain repair. This mechanism sets TB006 apart from all existing Alzheimer’s and dementia drugs.
TB006 has not yet received full FDA approval, but it is authorized for compassionate use under the Expanded Access Program (EAP). This allows patients with no other treatment options to access investigational therapies while they are still in clinical development.
TB006 is currently in Phase 2B clinical trials. Full FDA approval is anticipated in approximately four years, depending on ongoing trial outcomes.
The Expanded Access Program allows treatment of patients with mild, moderate, or late-stage Alzheimer’s or dementia, provided they meet the program’s inclusion criteria.
Yes. There are no upper age restrictions, though patients must be at least 55 years old to qualify for treatment.
Only one significant adverse reaction has been recorded to date, involving a patient with severe coronary artery disease. Overall, TB006 has shown a strong safety profile.
TB006 is administered via intravenous (IV) infusion, typically lasting one hour or more. Patients should be well-hydrated before the session. No additional pre- or post-treatment procedures are generally required.
Missed doses can simply be skipped. Resume your treatment as per the regular schedule.
Treatments are scheduled every 28 days (±5 days). If results plateau, your provider may pause treatment until further benefit is expected.
Results vary by individual and disease severity. Many patients notice improvement after the first treatment, while others may require up to 8 treatments. Most experience benefit within 3 sessions.
No. As TB006 is still investigational, insurance providers do not cover or reimburse for the treatment.
Yes. There are specific inclusion criteria for eligibility. An Authorized TB006 Provider will assess your eligibility.
The EAP allows patients with life-threatening conditions to access investigational treatments. In 2023, of the 83 drug applications submitted to the EAP, only TB006 received approval, underscoring its potential and safety.
Across thousands of treatments, TB006 has exhibited an excellent safety profile, with only one significant adverse event reported.
Yes, but only through clinical trials or the Expanded Access Program. It is not available for general prescription use.
Yes. Your provider may suggest lifestyle changes or complementary treatments that enhance the effectiveness of TB006 therapy.
No. TB006 must be administered by a trained, authorized TB006 provider. Visit tb006providers.com for a list of approved locations.
Yes—but only if you have a diagnosis of mild dementia. Parkinson’s alone does not qualify for TB006 treatment.
No. Eligibility is determined based on the EAP’s inclusion criteria. Consult with an Authorized TB006 Provider to find out if you qualify.
No. Clinical trials collect data to evaluate safety, efficacy, and dosage. In contrast, EAPs provide treatment to patients unable to join trials due to disease severity or other constraints.
Contact an Authorized TB006 Provider listed on the official website to begin the enrollment process.
Contact TrueBinding via their official website at www.truebinding.com.
In most cases, no. TB006 is highly selective and has no known interactions with common medications, including blood thinners and dementia drugs. However, avoid other monoclonal antibodies or NSAIDs that suppress the immune system without provider guidance.
Currently, financial assistance is limited. We remain hopeful that assistance programs will become available in the future.
TB006 has a low incidence of side effects. When they occur, they are usually mild and may include infusion site irritation, headaches, or temporary dizziness.
Yes. Patients have received TB006 for over two years with continued benefit and no reported long-term adverse effects.
Caregivers are often the first to notice improvements. Patients may not realize they’ve regained lost functions, as these changes often feel natural. We recommend caregivers maintain a daily log to track progress.
